.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Cerilliant
Accenture
Cantor Fitzgerald
Chubb
Daiichi Sankyo
US Army
Cipla
Colorcon
Boehringer Ingelheim

Generated: June 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,250,419

« Back to Dashboard

Claims for Patent: 7,250,419

Title:Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
Inventor(s): Hardern; David (Sutton Bonington, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (West Bridgford, GB), Guile; Simon (Loughborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/230,493
Patent Claims: 1. A compound selected from the group consisting of [1S-(1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.)]-3-[7-[2-(3,4-difluoroph- enyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3- -yl)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol, and pharmaceutically acceptable salts thereof.

2. The compound 1S-(1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.)]-3-[7-2-(3,4-difluorophen- yl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-y- l)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol.

3. A pharmaceutical composition comprising a compound as claimed in claim 1 in combination with a pharmaceutically acceptable diluent, adjuvant and/or carrier.

4. A pharmaceutical composition comprising a compound as claimed in claim 2 in combination with a pharmaceutically acceptable diluent, adjuvant and/or carrier.

5. A method of treatment of myocardial infarction which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 1.

6. A method of treatment of myocardial infarction which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 2.

7. A method of treatment of thrombotic stroke which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 1.

8. A method of treatment of thrombotic stroke which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 2.

9. A method of treatment of transient ischaemic attacks which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 1.

10. A method of treatment of transient ischaemic attacks which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 2.

11. A method of treatment of stable and unstable angina which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 1.

12. A method of treatment of stable and unstable angina which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 2.

13. A method of inhibiting platelet aggregation in a person which comprises administering a therapeutically effective amount of a compound according to claim 1 to said person.

14. A method of inhibiting platelet aggregation in a person which comprises administering a therapeutically effective amount of a compound according to claim 2 to said person.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Argus Health
US Department of Justice
McKinsey
Daiichi Sankyo
Federal Trade Commission
Medtronic
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot